Sign in
4

Changes in Ownership

DEXCOM INC Filed Acc 0001093557-23-000077

SVP Corporate Strategy-Develop sold 6,229 shares at $106.27 ($661,956)

  • SVP Corporate Strategy-Develop returned 6,204 shares (to the company)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I In the form
Dolan Matthew Vincent SVP Corporate Strategy-Develop 2023-03-10 Returned to the company −1,370 $111.40 $152,617 46,935 D
Dolan Matthew Vincent SVP Corporate Strategy-Develop 2023-03-10 Returned to the company −1,650 $111.40 $183,808 45,285 D
Dolan Matthew Vincent SVP Corporate Strategy-Develop 2023-03-10 Returned to the company −2,397 $111.40 $267,023 42,888 D
Dolan Matthew Vincent SVP Corporate Strategy-Develop 2023-03-10 Returned to the company −787 $111.40 $87,671 42,101 D
Dolan Matthew Vincent SVP Corporate Strategy-Develop 2023-03-13 Sale −6,229 $106.27 $661,956 35,872 D
Open-market sales · 6,229 sh · avg $106.27 · $661,956
Loading xslF345X03/edgardoc.xml…